Developer docs
API playgroundTry for free, no card

Search company profiles

Gamma Biosciences

Full company profile

uuid00025dq

Namestring
Gamma Biosciences
Legal namestring
Gamma Biosciences
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Gamma Biosciences is a private bioprocessing holding company founded in 2019 and headquartered in Menlo Park, California, that builds a portfolio of products and services for advanced biologic therapies, with a focus on cell and gene therapy and next-generation vaccine manufacturers. The company operates through a multi-subsidiary platform that covers adjacent stages of the bioprocessing workflow, including Astrea Bioseparations (bioseparation products, including the Nereus LentiHERO fit-for-purpose lentiviral vector purification solution), Nanopareil (next-generation purification technology), and BioMagnetic Solutions (magnetic-based bioprocessing solutions operating an ISO-certified GMP facility at Penn State's Innovation Park). Through Mirus Bio (acquired in 2021 and subsequently divested to Merck Group in August 2024), Gamma had exposure to viral vector bioprocessing and to lipid-polymer nanocomplex development for in vivo mRNA delivery, and a related mRNA delivery initiative was launched in January 2025.

The company's underlying technology stack is built around purification, separation, and delivery chemistries for complex biologics rather than around software or data platforms. Recent product and infrastructure moves — including the Nereus LentiHERO launch in September 2025 and the BioMagnetic Solutions GMP buildout in November 2025 — extend the platform from upstream purification IP into GMP-compliant manufacturing capacity for biopharma customers.

Gamma Biosciences makes money through B2B product sales and services to biopharmaceutical customers, primarily via enterprise field sales targeting gene therapy developers and vaccine manufacturers. The company has raised $200 million in funding from Kohlberg Kravis Roberts (KKR) and Univercells (round dated February 2020), and revenue is not publicly disclosed. The acquisition-heavy growth model — Nanopareil (2020), BioMagnetic Solutions (2021), Mirus Bio (2021), and the Mirus Bio divestiture to Merck (2024) — combined with new product launches and a GMP buildout, point to a roll-up strategy designed to assemble a vertically integrated bioprocessing platform serving the cell and gene therapy value chain.

Short descriptiontext

Gamma Biosciences is a private, Menlo Park-based bioprocessing holding company that builds purification, viral vector, mRNA delivery, and GMP manufacturing technologies for cell and gene therapy and vaccine developers through subsidiaries including Astrea Bioseparations, Nanopareil, and BioMagnetic Solutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioprocessing technologies, cell and gene therapy, viral vector purification, biologic therapy manufacturing, bioseparation products
Industry3 codes
PRIMARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Analytical Laboratory Instrument Manufacturing334516
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Bioprocessing Equipment and Consumables
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Bioprocessing Products and Services
TypeHardware Sales
Description

Develops and sells products and services to support biologic therapies, including viral vector purification solutions, mRNA delivery systems, and related bioprocessing technologies. Revenue is generated through product sales to life sciences and biopharma customers.

pitchbook.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Nereus LentiHERO
Description

Fit-for-purpose solution for lentiviral vector purification developed by Astrea Bioseparations

gammabiosciences.com
Core offering1 text field

Gamma Biosciences is a life sciences platform company that develops and supplies bioprocessing products and services to support the manufacturing of biologic therapies, including gene therapies and next-generation vaccines. Its portfolio spans viral vector purification technologies, mRNA delivery systems, bioseparation chromatography products, and GMP-grade manufacturing services delivered through operating subsidiaries such as Astrea Bioseparations, Mirus Bio, Nanopareil, and BioMagnetic Solutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Acquisition of Nanopareil advances next-generation purification capabilities
+2 more records
Product overview1 text field

Gamma Biosciences is a life sciences company founded in 2019 and based in Menlo Park, California, that develops products and services to support biologic therapies. The company operates as a platform of subsidiaries and acquired companies in the bioprocessing industry, with a portfolio that includes Astrea Bioseparations (bioseparation products), Mirus Bio (gene therapy and vaccine technologies), Nanopareil (purification capabilities), and BioMagnetic Solutions (magnetic-based solutions). The company has raised $200 million in funding and serves the cell and gene therapy sector with a focus on manufacturing scalability, viral vector bioprocessing, and purification solutions.

Product and service5 records
1Nereus LentiHERO
CategoryBioprocessing Purification Products
Description

A fit-for-purpose purification solution developed by Astrea Bioseparations for lentiviral vector purification, supporting cell and gene therapy manufacturing workflows. Intended for biopharmaceutical manufacturers developing gene therapies.

2Astrea Bioseparations Bioseparation Products
CategoryBioseparation Products and Services
Description

Bioseparation chromatography products and services supporting biologic therapy manufacturing, including lentiviral vector purification solutions for gene therapy developers.

3Mirus Bio Gene Therapy and Vaccine Products
CategoryGene Therapy and Vaccine Delivery Products
Description

Products and technologies for gene therapy and next-generation vaccine development, including lipid-polymer nanocomplexes for in vivo mRNA delivery. Sold to biopharma companies developing cell and gene therapies and vaccines.

4Nanopareil Next-Generation Purification Products
CategoryPurification Technologies
Description

Next-generation purification technologies integrated into Astrea Bioseparations' portfolio, supporting advanced therapy bioprocessing.

5BioMagnetic Solutions Magnetic-Based Bioprocessing Products and GMP Manufacturing
CategoryBioprocessing and Contract Manufacturing Services
Description

Magnetic-based bioprocessing solutions and ISO-certified GMP manufacturing services provided from the Penn State Innovation Park facility, available to biopharmaceutical customers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-16
Description

BioMagnetic Solutions, a Gamma Biosciences subsidiary, confirmed ISO certifications and GMP facility build at Innovation Park at Penn State. This partnership provides manufacturing infrastructure for bioprocessing operations.

Strategic tierMinorTypeOthersAnnounced on2024-08-01
Description

Merck Group closed acquisition of Mirus Bio, which was previously a Gamma Biosciences subsidiary. This represents a divestiture rather than a partnership.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bioprocessing giant (Danaher subsidiary) supplying filtration, chromatography, and single-use systems for biologics and viral vector manufacturing. Overlaps directly with Gamma's Astrea Bioseparations and lentiviral purification portfolio.

TypeBroad incumbent
Description

Global bioprocessing supplier of upstream/downstream equipment and consumables for cell and gene therapy production. Competes with Gamma across viral vector purification and bioprocess tools.

TypeDirect peer
Description

Pure-play bioprocessing tools company specializing in chromatography, filtration, and process analytics. Directly comparable to Astrea Bioseparations in bioseparation consumables.

4Merck KGaA (Life Science / MilliporeSigma)
TypeBroad incumbent
Description

Bioprocessing incumbent that acquired Mirus Bio from Gamma in 2024. Now a direct competitor in viral vector bioprocessing and mRNA delivery, and validates Gamma's prior Mirus Bio thesis.

TypeBroad incumbent
Description

Diversified life sciences giant with viral vector services (Brammer Bio) and bioproduction capabilities. Competes across the full cell and gene therapy bioprocessing value chain.

TypeDirect peer
Description

Leading CDMO with significant cell and gene therapy manufacturing services and bioprocess tools. Comparable business model combining GMP services with proprietary bioprocessing technology.

TypeBroad incumbent
Description

Supplier of bioprocessing inputs, single-use solutions, and laboratory products serving biopharma manufacturers. Overlaps with Gamma's consumables and bioprocessing product portfolio.

TypeEmerging player
Description

Life sciences reagent and bioprocessing consumables supplier expanding into cell and gene therapy workflow tools. Emerging competitor in purification and process analytics.

TypeDirect peer
Description

CDMO offering viral vector and cell therapy manufacturing services with proprietary process platforms. Closely aligned with Gamma's gene therapy manufacturing focus.

TypeRegional player
Description

Cell and gene therapy CDMO with substantial viral vector manufacturing capacity. Operates primarily in Asia-Pacific but serves global biopharma, comparable in scale and capability.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gamma Biosciences

Bioprocessing Equipment and Consumablesgammabiosciences.com

Gamma Biosciences is a private, Menlo Park-based bioprocessing holding company that builds purification, viral vector, mRNA delivery, and GMP manufacturing technologies for cell and gene therapy and vaccine developers through subsidiaries including Astrea Bioseparations, Nanopareil, and BioMagnetic Solutions.

What Gamma Biosciences does

Gamma Biosciences is a private bioprocessing holding company founded in 2019 and headquartered in Menlo Park, California, that builds a portfolio of products and services for advanced biologic therapies, with a focus on cell and gene therapy and next-generation vaccine manufacturers. The company operates through a multi-subsidiary platform that covers adjacent stages of the bioprocessing workflow, including Astrea Bioseparations (bioseparation products, including the Nereus LentiHERO fit-for-purpose lentiviral vector purification solution), Nanopareil (next-generation purification technology), and BioMagnetic Solutions (magnetic-based bioprocessing solutions operating an ISO-certified GMP facility at Penn State's Innovation Park). Through Mirus Bio (acquired in 2021 and subsequently divested to Merck Group in August 2024), Gamma had exposure to viral vector bioprocessing and to lipid-polymer nanocomplex development for in vivo mRNA delivery, and a related mRNA delivery initiative was launched in January 2025.

The company's underlying technology stack is built around purification, separation, and delivery chemistries for complex biologics rather than around software or data platforms. Recent product and infrastructure moves — including the Nereus LentiHERO launch in September 2025 and the BioMagnetic Solutions GMP buildout in November 2025 — extend the platform from upstream purification IP into GMP-compliant manufacturing capacity for biopharma customers.

Gamma Biosciences makes money through B2B product sales and services to biopharmaceutical customers, primarily via enterprise field sales targeting gene therapy developers and vaccine manufacturers. The company has raised $200 million in funding from Kohlberg Kravis Roberts (KKR) and Univercells (round dated February 2020), and revenue is not publicly disclosed. The acquisition-heavy growth model — Nanopareil (2020), BioMagnetic Solutions (2021), Mirus Bio (2021), and the Mirus Bio divestiture to Merck (2024) — combined with new product launches and a GMP buildout, point to a roll-up strategy designed to assemble a vertically integrated bioprocessing platform serving the cell and gene therapy value chain.

Gamma Biosciences firmographics

Firmographics
Name
Gamma Biosciences
Legal name
Gamma Biosciences
Website
https://gammabiosciences.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Gamma Biosciences is a private, Menlo Park-based bioprocessing holding company that builds purification, viral vector, mRNA delivery, and GMP manufacturing technologies for cell and gene therapy and vaccine developers through subsidiaries including Astrea Bioseparations, Nanopareil, and BioMagnetic Solutions.
Ownership category
akta.pro rank

Gamma Biosciences industry classification

Industry
Product category
Bioprocessing Equipment and Consumables
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Bioprocessing technologies
  • Cell and gene therapy
  • Viral vector purification
  • Biologic therapy manufacturing
  • Bioseparation products

Where Gamma Biosciences is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Gamma Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Bioprocessing Products and Services: Develops and sells products and services to support biologic therapies, including viral vector purification solutions, mRNA delivery systems, and related bioprocessing technologies. Revenue is generated through product sales to life sciences and biopharma customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Gamma Biosciences product offering

Product offering

Core offering

Gamma Biosciences is a life sciences platform company that develops and supplies bioprocessing products and services to support the manufacturing of biologic therapies, including gene therapies and next-generation vaccines. Its portfolio spans viral vector purification technologies, mRNA delivery systems, bioseparation chromatography products, and GMP-grade manufacturing services delivered through operating subsidiaries such as Astrea Bioseparations, Mirus Bio, Nanopareil, and BioMagnetic Solutions.

Product overview

Gamma Biosciences is a life sciences company founded in 2019 and based in Menlo Park, California, that develops products and services to support biologic therapies. The company operates as a platform of subsidiaries and acquired companies in the bioprocessing industry, with a portfolio that includes Astrea Bioseparations (bioseparation products), Mirus Bio (gene therapy and vaccine technologies), Nanopareil (purification capabilities), and BioMagnetic Solutions (magnetic-based solutions). The company has raised $200 million in funding and serves the cell and gene therapy sector with a focus on manufacturing scalability, viral vector bioprocessing, and purification solutions.

Differentiator

Problem solved

Functional benefit

Brands

  • Nereus LentiHERO: Fit-for-purpose solution for lentiviral vector purification developed by Astrea Bioseparations

Products and services

  • Nereus LentiHERO A fit-for-purpose purification solution developed by Astrea Bioseparations for lentiviral vector purification, supporting cell and gene therapy manufacturing workflows. Intended for biopharmaceutical manufacturers developing gene therapies.
  • Astrea Bioseparations Bioseparation Products Bioseparation chromatography products and services supporting biologic therapy manufacturing, including lentiviral vector purification solutions for gene therapy developers.
  • Mirus Bio Gene Therapy and Vaccine Products Products and technologies for gene therapy and next-generation vaccine development, including lipid-polymer nanocomplexes for in vivo mRNA delivery. Sold to biopharma companies developing cell and gene therapies and vaccines.
  • Nanopareil Next-Generation Purification Products Next-generation purification technologies integrated into Astrea Bioseparations' portfolio, supporting advanced therapy bioprocessing.
  • BioMagnetic Solutions Magnetic-Based Bioprocessing Products and GMP Manufacturing Magnetic-based bioprocessing solutions and ISO-certified GMP manufacturing services provided from the Penn State Innovation Park facility, available to biopharmaceutical customers.

Quantifiable outcome

  • Acquisition of Nanopareil advances next-generation purification capabilities
  • +2 more outcomes

Companies that use Gamma Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Gamma Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Gamma Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Penn State Innovation ParkcoreStrategic or Co-development Partner · 16 November 2025BioMagnetic Solutions, a Gamma Biosciences subsidiary, confirmed ISO certifications and GMP facility build at Innovation Park at Penn State. This partnership provides manufacturing infrastructure for bioprocessing operations.
  • Merck GroupminorOthers · 1 August 2024Merck Group closed acquisition of Mirus Bio, which was previously a Gamma Biosciences subsidiary. This represents a divestiture rather than a partnership.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Gamma Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Cytiva: Bioprocessing giant (Danaher subsidiary) supplying filtration, chromatography, and single-use systems for biologics and viral vector manufacturing. Overlaps directly with Gamma's Astrea Bioseparations and lentiviral purification portfolio.
  • Sartorius: Global bioprocessing supplier of upstream/downstream equipment and consumables for cell and gene therapy production. Competes with Gamma across viral vector purification and bioprocess tools.
  • Merck KGaA (Life Science / MilliporeSigma): Bioprocessing incumbent that acquired Mirus Bio from Gamma in 2024. Now a direct competitor in viral vector bioprocessing and mRNA delivery, and validates Gamma's prior Mirus Bio thesis.
  • Thermo Fisher Scientific: Diversified life sciences giant with viral vector services (Brammer Bio) and bioproduction capabilities. Competes across the full cell and gene therapy bioprocessing value chain.
  • Avantor: Supplier of bioprocessing inputs, single-use solutions, and laboratory products serving biopharma manufacturers. Overlaps with Gamma's consumables and bioprocessing product portfolio.

Direct peers

  • Repligen: Pure-play bioprocessing tools company specializing in chromatography, filtration, and process analytics. Directly comparable to Astrea Bioseparations in bioseparation consumables.
  • Lonza: Leading CDMO with significant cell and gene therapy manufacturing services and bioprocess tools. Comparable business model combining GMP services with proprietary bioprocessing technology.
  • AGC Biologics: CDMO offering viral vector and cell therapy manufacturing services with proprietary process platforms. Closely aligned with Gamma's gene therapy manufacturing focus.

Emerging players

  • Bio-Techne: Life sciences reagent and bioprocessing consumables supplier expanding into cell and gene therapy workflow tools. Emerging competitor in purification and process analytics.

Regional players

  • WuXi Advanced Therapies: Cell and gene therapy CDMO with substantial viral vector manufacturing capacity. Operates primarily in Asia-Pacific but serves global biopharma, comparable in scale and capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Gamma Biosciences social profiles

Digital presence

Gamma Biosciences compliance and trust

Trust signal

Compliance1 record

Gamma Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gamma Biosciences leadership team

Management profile

Number of profiles

Profiles3 records

Gamma Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Gamma Biosciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gamma Biosciences M&A and investment

M&A and investment

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gamma Biosciences

What does Gamma Biosciences do?

Gamma Biosciences is a life sciences platform company that develops and supplies bioprocessing products and services to support the manufacturing of biologic therapies, including gene therapies and next-generation vaccines. Its portfolio spans viral vector purification technologies, mRNA delivery systems, bioseparation chromatography products, and GMP-grade manufacturing services delivered through operating subsidiaries such as Astrea Bioseparations, Mirus Bio, Nanopareil, and BioMagnetic Solutions.

Is Gamma Biosciences a public or private company?

Gamma Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gamma Biosciences founded?

Gamma Biosciences was founded in 2019. It employs 1 to 10 people.

Where is Gamma Biosciences based?

Gamma Biosciences is headquartered in Menlo Park, United States, in the North America region.

How does Gamma Biosciences make money?

One revenue line is on record: bioprocessing Products and Services.

Who are Gamma Biosciences's main competitors?

Broad incumbents on record are Cytiva, Sartorius, Merck KGaA (Life Science / MilliporeSigma), Thermo Fisher Scientific and Avantor. Direct peers are Repligen, Lonza and AGC Biologics. Bio-Techne is listed as an emerging player. WuXi Advanced Therapies is listed as a regional player.

Does Gamma Biosciences have an API?

No public API is recorded for Gamma Biosciences.

What industry is Gamma Biosciences in?

Gamma Biosciences's product category is Bioprocessing Equipment and Consumables. Its primary akta.pro industry code is HLAAAKAD, Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PitchBookGamma Biosciences 2025 Company Profile: Valuation, Funding & InvestorsGamma Biosciences, a private life sciences company founded in 2019 and based in Menlo Park, California, develops products and services to support biologic therapies. The company has raised $200 million in funding and has a subsidiary and competitors in the bioprocessing industry.StartupSeekerGamma Biosciences - Funding: $200M+Gamma Biosciences, a bioprocessing solutions provider founded in 2019, has raised over $200 million in funding. The company develops advanced cell culture and purification techniques to accelerate the manufacturing of biologic therapies for patients.MirusbioGamma Biosciences Announces Sale of Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 Million – Mirus BioGamma Biosciences announced an agreement to sell its operating company Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 million in cash. The transaction, which involves Mirus Bio's transfection solutions for cell and gene therapy applications, is expected to close in the third quarter of 2024 pending regulatory approvals.Law360Merck To Pay $600M For KKR-Backed Life Sciences BizGamma Biosciences agreed to sell its operating company Mirus Bio to Merck KGaA for $600 million in cash. The deal is under the guidance of Sidley Austin LLP.YahooMerck KGaA to buy gene therapy tools maker for $600MMerck KGaA agreed to buy Mirus Bio for $600 million to strengthen its viral vector manufacturing capabilities. The acquisition aims to address a supply bottleneck in contract manufacturing, with the deal expected to close in the third quarter.ContractpharmaMerck KGaA to Acquire Gamma Biosciences' Mirus Bio for $600MMerck KGaA agreed to acquire Gamma Biosciences' Mirus Bio for $600 million in cash. Mirus Bio provides transfection solutions for cell and gene therapy, including GMP products for AAV and LV production. The deal is expected to close in the third quarter of 2024.BioSpaceGamma Biosciences Announces Sale of Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 MillionGamma Biosciences said it has agreed with Merck KGaA of Darmstadt, Germany, to acquire its operating company Mirus Bio for $600 million in cash. Gamma, backed by KKR, acquired a controlling stake in Mirus Bio in 2021 and supported its growth, including the launch of VirusGEN GMP and RevIT AAV Enhancer. Closing is expected in the third quarter of 2024, subject to US regulatory approvals.PR NewswireGamma Biosciences Announces Sale of Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 MillionMerck KGaA agreed to acquire Gamma Biosciences' operating company Mirus Bio for $600 million in cash. The deal is expected to close in the third quarter of 2024, subject to US regulatory approvals. Mirus Bio provides transfection solutions for cell and gene therapy applications.GammabiosciencesGamma Biosciences and Lonza Collaborate to Co-develop Reagents for Clinical Cell Selection in the Cocoon® Platform — Gamma BiosciencesGamma Biosciences and Lonza have entered a multi-year strategic collaboration to co-develop clinical-grade FerroSelect reagents for use in Lonza’s Cocoon® Platform. Under the agreement, Gamma Biosciences will supply its proprietary ferrofluid technology to support the development of CAR-T and other immunotherapeutic products.